Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

The effects of tranylcypromine on osteoclastogenesis in vitro and in vivo.

Liu Z, Yang K, Yan X, Wang T, Jiang T, Zhou Q, Qi J, Qian N, Zhou H, Chen B, Huang P, Guo L, Zhang X, Xu X, Jiang M, Deng L.

FASEB J. 2019 Jul 10:fj201802242RR. doi: 10.1096/fj.201802242RR. [Epub ahead of print]

PMID:
31291555
2.

Prostate MRI and transperineal TRUS/MRI fusion biopsy for prostate cancer detection: clinical practice updates.

Martorana E, Pirola GM, Aisa MC, Scialpi P, Di Blasi A, Saredi G, D'Andrea A, Signore S, Grisanti R, Scialpi M.

Turk J Urol. 2019 Jul 1;45(4):237-244. doi: 10.5152/tud.2019.19106. Review.

3.

Extramammary Paget Disease of the Scrotum: A Contemporary Clinicopathologic Analysis of 20 Cases in the United States.

Shabihkhani M, Patil P, Murati Amador B, Plaza JA, Osunkoya AO, Lombardo KA, Epstein JI, Matoso A.

Appl Immunohistochem Mol Morphol. 2019 Jul 8. doi: 10.1097/PAI.0000000000000789. [Epub ahead of print]

PMID:
31290785
4.

Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study.

Al Hussein Al Awamlh B, Shoag JE, Ravikumar V, Posada L, Taylor BL, van der Mijn JC, Khan AI, Fainberg J, Al Hussein Alawamleh O, Scherr DS.

J Urol. 2019 Jul 10:101097JU0000000000000433. doi: 10.1097/JU.0000000000000433. [Epub ahead of print]

PMID:
31290707
5.

Development and validation of prognostic nomograms for patients with metastatic prostate cancer.

Jiang WD, Yuan PC.

Int Urol Nephrol. 2019 Jul 9. doi: 10.1007/s11255-019-02224-z. [Epub ahead of print]

PMID:
31289983
6.

Importance of the correct assessment of bone fractures in the clinical management of metastatic castration-resistant prostate cancer treated with radium-223: A case report.

Rizzini EL, Ghedini P, Cardano R, Bellarosa C, Morganti AG, Fanti S, Monari F.

Mol Clin Oncol. 2019 Jul;11(1):63-66. doi: 10.3892/mco.2019.1852. Epub 2019 May 6.

7.

Definition of fields margins for the optimized 2D radiotherapy of prostate carcinoma.

Buwenge M, Perrone M, Siepe G, Capocaccia I, Woldemariam AA, Wondemagegnhu T, Uddin KAFM, Sumon MA, Galofaro E, Macchia G, Deodato F, Cilla S, Morganti AG.

Mol Clin Oncol. 2019 Jul;11(1):37-42. doi: 10.3892/mco.2019.1855. Epub 2019 May 8.

8.

Erratum: CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.

Terry S, El-Sayed IY, Destouches D, Maillé P, Nicolaiew N, Ploussard G, Semprez F, Pimpie C, Beltran H, Londono-Vallejo A, Allory Y, de la Taille A, Salomon DS, Vacherot F.

Oncotarget. 2019 Jun 25;10(41):4247-4248. doi: 10.18632/oncotarget.27038. eCollection 2019 Jun 25.

9.

Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme.

Malik Z, Heidenreich A, Bracarda S, Ardavanis A, Parente P, Scholz HJ, Ozatilgan A, Ecstein-Fraisse E, Hitier S, Di Lorenzo G.

Oncotarget. 2019 Jun 25;10(41):4161-4168. doi: 10.18632/oncotarget.27031. eCollection 2019 Jun 25.

10.

Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging.

Tolkach Y, Goltz D, Kremer A, Ahmadzadehfar H, Bergheim D, Essler M, Lam M, de Keizer B, Fischer HP, Kristiansen G.

Oncotarget. 2019 Jun 25;10(41):4149-4160. doi: 10.18632/oncotarget.27024. eCollection 2019 Jun 25.

11.

The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy.

Li H, Wang Z, Zhang Y, Sun G, Ding B, Yan L, Liu H, Guan W, Hu Z, Wang S, Cheng F, Xu H, Zhang X, Ye Z.

J Cancer. 2019 Jun 2;10(14):3102-3111. doi: 10.7150/jca.30384. eCollection 2019.

12.

Inhibition of proliferation and migration of melanoma cells by ketoconazole and Ganoderma immunomodulatory proteins.

Lu CT, Leong PY, Hou TY, Kang YT, Chiang YC, Hsu CT, Lin YD, Ko JL, Hsiao YP.

Oncol Lett. 2019 Jul;18(1):891-897. doi: 10.3892/ol.2019.10355. Epub 2019 May 14.

13.

Trichostatin A inhibits proliferation of PC3 prostate cancer cells by disrupting the EGFR pathway.

Zhang H, Zhao X, Liu H, Jin H, Ji Y.

Oncol Lett. 2019 Jul;18(1):687-693. doi: 10.3892/ol.2019.10384. Epub 2019 May 21.

14.

Transmembrane protein 64 modulates prostate tumor progression by regulating Wnt3a secretion.

Moon YH, Lim W, Jeong BC.

Oncol Lett. 2019 Jul;18(1):283-290. doi: 10.3892/ol.2019.10324. Epub 2019 May 6.

15.

125I low-dose-rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer.

Zhou Z, Yan W, Zhou Y, Zhang F, Li H, Ji Z.

Oncol Lett. 2019 Jul;18(1):72-80. doi: 10.3892/ol.2019.10279. Epub 2019 Apr 22.

16.

Defining and Measuring Adherence in Observational Studies Assessing Outcomes of Real-world Active Surveillance for Prostate Cancer: A Systematic Review.

Kith G, Lisker S, Sarkar U, Barr-Walker J, Breyer BN, Palmer NR.

Eur Urol Oncol. 2019 Jul 6. pii: S2588-9311(19)30084-7. doi: 10.1016/j.euo.2019.06.009. [Epub ahead of print] Review.

PMID:
31288992
17.

Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways.

Barrett T, Slough R, Sushentsev N, Shaida N, Koo BC, Caglic I, Kozlov V, Warren AY, Thankappannair V, Pinnock C, Shah N, Saeb-Parsy K, Gnanapragasam VJ, Sala E, Kastner C.

Clin Radiol. 2019 Jul 6. pii: S0009-9260(19)30279-X. doi: 10.1016/j.crad.2019.06.004. [Epub ahead of print]

PMID:
31288924
18.

SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy.

Li X, Zhang W, Song J, Zhang X, Ran L, He Y.

Clin Epigenetics. 2019 Jul 9;11(1):99. doi: 10.1186/s13148-019-0693-2.

19.

Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases.

Zhu Y, Wang Y, Qian Z, Pan J, Liu Q, Dong B, Xue W.

BMC Cancer. 2019 Jul 9;19(1):676. doi: 10.1186/s12885-019-5876-x.

20.

CRA toolbox: software package for conditional robustness analysis of cancer systems biology models in MATLAB.

Bianconi F, Antonini C, Tomassoni L, Valigi P.

BMC Bioinformatics. 2019 Jul 9;20(1):385. doi: 10.1186/s12859-019-2933-z.

Supplemental Content

Loading ...
Support Center